Work

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

Year: 2010

Type: article

Source: Investigational New Drugs

DOI: 10.1007/s10637-010-9567-3

Authors: Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman, Patricia L. Myskowski

Institutions: Memorial Sloan Kettering Cancer Center, Stony Brook University Hospital

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Dermatology Foundation, AstraZeneca, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2134758896

FWCI: 6.882

Cites: 22

Cited by: 103

Related to: 10